Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS™ (Infliximab), a Biosimilar of Remicade, in Korea

Dateline City: KENILWORTH, N.J. Samsung Bioepis’ Second Immunology Biosimilar Approved, to be Commercialized Under Partnership with Merck KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Samsung Bioepis Co., Ltd. has received approval of RENFLEXIS™ (infliximab), a biosimilar of the immunology medicine Remicade, by the Ministry of Food and Drug Safety (MFDS) in Korea. Merck will commercialize Samsung Bioepis’ RENFLEXIS in Korea as part of Merck’s commercialization partnership with Samsung Bioepis to offer high-quality biosimilar alternatives to existing biologic medicines. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK biosimilar NYSE:MRK RENFLEXIS Source Type: news